Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lowbush blueberry (Vaccinium angustifolium), also known as wild blueberry, is a polyphenol-rich fruit native to North America. It is widely recognized for its high concentration of anthocyanins, which contribute to its potent antioxidant and anti-inflammatory properties. In preclinical research, lowbush blueberry extracts have demonstrated neuroprotective effects in models of cerebral ischemia/reperfusion injury by downregulating pro-inflammatory markers such as iNOS and TNF-alpha and upregulating protective microRNAs (miR-146a and miR-21). Additionally, it is investigated as a functional feed additive in veterinary medicine, specifically in poultry, to modulate the cecal microbiome and resistome, potentially serving as an alternative to traditional antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lowbush blueberry.